Algeta, a cancer therapeutics company, and the Institute for Energy Technology (IFE), based in Oslo, are collaborating to manufacture and supply Alpharadin for future commercial use and in clinical trials.
Alpharadin (radium-223 chloride) is a highly targeted alpha-pharmaceutical under clinical evaluation to improve survival in patients with bone metastases from advanced prostate cancer.
In addition to prostate cancer, Algeta believes Alpharadin will also have potential in treating bone metastases originating from other types of cancer, such as breast, lung, kidney and thyroid.
This is the first part of Algeta's manufacturing strategy to produce and supply Alpharadin to the needs of ongoing ALSYMPCA (ALpharadin in SYmtomatic Prostate CAncer) phase III study and planned clinical trials in other cancer indications, according to the company.
Algeta, also based in Oslo, Norway, said the agreement will also supply the expected commercial demand around the world following its approval and worldwide launch in collaboration with Bayer Schering Pharma AG.